Oxford Biomedica PLC £3 million Innovate UK grant (6474C)
23 January 2018 - 8:45PM
UK Regulatory
TIDMOXB
RNS Number : 6474C
Oxford Biomedica PLC
23 January 2018
Oxford BioMedica announces GBP3 million grant awarded by
Innovate UK
London, UK - 23 January 2018: Oxford BioMedica plc ("Oxford
BioMedica" or "the Group") (LSE:OXB), a leading gene and cell
therapy group, has announced it that has been awarded a GBP3
million grant by the UK's innovation agency, Innovate UK, to
support the UK's efforts to produce viral vectors and ensure
adequate supply to meet future demand. Reference: corresponding
Innovate UK announcement here:
https://www.gov.uk/government/news/improved-healthcare-for-all-pioneering-projects-get-funding
The aims of this grant are closely aligned with the current
government national priorities to make the UK a global hub for
manufacturing advanced therapies, which will benefit economic
growth and create and retain more highly skilled employment.
The grant will be used to support investment in equipment for
vector development, vector manufacture, storage and analytical
equipment, as well as other items that are key for the operation of
vector GMP facilities. In addition, a small part of the grant will
be used to support the planning for the transition of GMP suites
from the use of adherent to suspension cultures.
John Dawson, Chief Executive Officer of Oxford BioMedica,
commented: "We are delighted that the Innovate UK grant will to
keep the UK at the forefront of innovation in industrial viral
vector manufacturing. Viral vectors are a crucial component of cell
and gene therapies, which offer unprecedented promise for the
treatment, long-term management or cure of disease. We are pleased
that Oxford BioMedica has been selected to contribute our expertise
to ensure continued and uninterrupted supply to meet future viral
vector demand."
- Ends -
For further information, please
contact:
Oxford BioMedica plc: Tel: +44 (0)1865
John Dawson, Chief Executive Officer 783 000
Stuart Paynter, Chief Financial
Officer
Consilium Strategic Communications Tel: +44 (0)20
Mary-Jane Elliott/Matthew Neal/Philippa 3709 5700
Gardner/Laura Thornton
Notes for editors
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy
group focused on developing life changing treatments for serious
diseases. Oxford BioMedica and its subsidiaries (the "Group") have
built a sector leading lentiviral vector delivery platform
(LentiVector(R) ), which the Group leverages to develop in vivo and
ex vivo products both in-house and with partners. The Group has
created a valuable proprietary portfolio of gene and cell therapy
product candidates in the areas of oncology, ophthalmology and CNS
disorders. The Group has also entered into a number of
partnerships, including with Novartis, Sanofi, GSK, Orchard
Therapeutics and Immune Design, through which it has long-term
economic interests in other potential gene and cell therapy
products. Oxford BioMedica is based across several locations in
Oxfordshire, UK and employs more than 300 people. Further
information is available at www.oxfordbiomedica.co.uk.
About Innovate UK
Innovate UK is the UK's innovation agency. It works with people,
companies and partner organisations to find and drive the science
and technology innovations that will grow the UK economy. For
further information visit: www.innovateuk.gov.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCPGUWCGUPRUBW
(END) Dow Jones Newswires
January 23, 2018 04:45 ET (09:45 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024